A Prospective Randomized Trial on Mycophenolate Mofetil in Risk Penetrating Keratoplasty

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2006
The purpose of this prospectively randomized multicentre study was to prove the efficacy and safety of mycophenolate mofetil (MMF) to preventing graft rejection and improvement of clear graft survival following high-risk keratoplasty. The patients of the MMF group receive MMF orally 2x1 g daily for 6 months. Endpoints were immune reaction free and clear graft survival and the occurence of side-effects.
Epistemonikos ID: 8e16607bd2c001a624a63cd0d709d602a155b3cd
First added on: May 04, 2024